Squarepoint
ALLO icon

Squarepoint’s Allogene Therapeutics ALLO Stock Holding History

Squarepoint’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$603K Buy
376,940
+135,416
+56% +$258K ﹤0.01% 3235
2026
Q2 		$502K Buy
241,524
+125,145
+108% +$275K ﹤0.01% 3424
2026
Q1 		$284K Buy
116,379
+11,723
+11% +$23.5K ﹤0.01% 3754
2025
Q4 		$143K Sell
104,656
-163,388
-61% -$216K ﹤0.01% 3959
2025
Q3 		$332K Buy
268,044
+249,978
+1,384% +$298K ﹤0.01% 3585
2025
Q2 		$20.4K Sell
18,066
-308,459
-94% -$410K ﹤0.01% 4390
2025
Q1 		$477K Buy
326,525
+306,180
+1,505% +$577K ﹤0.01% 3345
2024
Q4 		$43.3K Sell
20,345
-168,152
-89% -$415K ﹤0.01% 4867
2024
Q3 		$528K Buy
188,497
+61,869
+49% +$165K ﹤0.01% 3049
2024
Q2 		$295K Buy
+126,628
New +$374K ﹤0.01% 3440
2023
Q4 		– Sell
-121,792
Closed -$386K – 3970
2023
Q3 		$386K Buy
121,792
+71,855
+144% +$315K ﹤0.01% 2978
2023
Q2 		$248K Sell
49,937
-6,838
-12% -$37K ﹤0.01% 3087
2023
Q1 		$280K Sell
56,775
-143,589
-72% -$921K ﹤0.01% 2614
2022
Q4 		$1.26M Sell
200,364
-45,958
-19% -$425K 0.01% 1661
2022
Q3 		$2.66M Buy
+246,322
New +$3.35M 0.01% 1131
2022
Q2 		– Sell
-269,320
Closed -$2.45M – 2846
2022
Q1 		$2.45M Buy
+269,320
New +$2.81M 0.01% 1036
2021
Q1 		– Sell
-15,792
Closed -$399K – 3056
2020
Q4 		$399K Buy
15,792
+9,892
+168% +$322K ﹤0.01% 1983
2020
Q3 		$222K Buy
+5,900
New +$222K ﹤0.01% 2014
2020
Q1 		– Sell
-54,596
Closed -$1.42M – 1825
2019
Q4 		$1.42M Buy
54,596
+46,049
+539% +$1.27M 0.01% 1109
2019
Q3 		$233K Sell
8,547
-1,854
-18% -$52.8K ﹤0.01% 2012
2019
Q2 		$279K Sell
10,401
-2,599
-20% -$72.4K ﹤0.01% 1955
2019
Q1 		$376K Buy
+13,000
New +$377K ﹤0.01% 1636

Other funds holding ALLO

Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Squarepoint's ALLO Position: Q3 2026 in Review

Squarepoint increased its Allogene Therapeutics (ALLO) stake by 56% in Q3 2026, buying an estimated $258K and bringing the position to 376,940 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #3235.

Squarepoint first reported a position in ALLO in Q1 2019 and has held it in 22 quarters since. The position peaked at $2.66M in Q3 2022. 105 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Squarepoint held 376,940 shares of Allogene Therapeutics worth $603K as of Q3 2026.
  • Squarepoint bought 135,416 Allogene Therapeutics shares in Q3 2026, an estimated $258K.
  • Allogene Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3235 holding.
  • Squarepoint first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • Squarepoint's Allogene Therapeutics position peaked at $2.66M in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.